

## Pre-exposure prophylaxis (PrEP) **Expanding options for HIV prevention**

million

million



The Joint Programme's contribution

**ADVOCACY TECHNICAL SUPPORT CAPACITY BUILDING POLICY GUIDANCE COMMUNITY-LED RESPONSE** RESOURCES MOBILIZATION STRATEGIC INFORMATION



150 out of 165 reporting countries have adopted WHO recommendations on PrEP in their national guidelines

21 countries now include PrEP in their health benefit and financing packages

Scale up PrEP access especially in Kenya (over 918 000), South Africa (over 800 000), Thailand (over 26 000) and Viet Nam (over 67 000)



The Dapivirine ring is recommended by WHO as a prevention choice

Updates on oral PrEP + Dapivirine vaginal ring



Kenya is the first sub-Saharan African country to roll out PrEP reaching over 30 000 people in mid-2019

WHO update recommendations for event-driven oral PrEP to prevent HIV for men who have sex with men

Brazil starts provision of PrEP for HIV prevention in key populations at high risk through 35 sites across the country

South Africa is the first country in Africa to approve the use of antiretroviral medicines for prevention

WHO implementation tool PrEP of HIV infection

WHO consolidated quidelines on HIV prevention, diagnosis, treatment and care for key populations



Eswatini, Malawi, Ukraine, Zambia, and Zimbabwe start rolling out cabotegravir (CAB-LA)

Long-acting injectable lenacapavir shown to be effective for HIV prevention in women, men and transgender women

WHO updates implementation tool for PrEP of HIV infection

- Zimbabwe is the first country in Africa to announce regulatory approval of CAB-LA
- WHO launches new implementation guidance for differentiated and simplified PrEP
- WHO recommends long-acting injectable Cabotegravir for HIV prevention
- UNAIDS guidance for PrEP target-setting for key and high-priority populations

million

million

Brazil provides PrEP through the public health system, the first in the region

million

2018

Thailand shifts from PrEP trials to roll out among key groups at high risk through facilities and community led services

Viet Nam announces a national plan to roll out PrEP across 11 provinces

Tenofovir Disoproxil Fumarate (TDF) identified as a prevention choice WHO guideline on when to start antiretroviral

therapy and on PrEP for HIV



and transgender women who have sex with men at high risk







WHO guidance on Oral PrEP for serodiscordant couples, men



















